NCT04655313 - Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

January 12, 2022

Study Completion Date

January 12, 2022

Conditions

PsoriasisPlaque Psoriasis

Interventions

DRUG

ARQ-151 cream 0.3%

ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks

Trial Locations (17)

33016

Arcutis Clinical Site 501, Hialeah

33146

Arcutis Clinical Site 502, Coral Gables

33155

Arcutis Clinical Site 507, Miami

33428

Arcutis Clinical Site 510, Boca Raton

33484

Arcutis Clinical Site 513, Delray Beach

35223

Arcutis Clinical Site 503, Mountain Brook

47906

Arcutis Clinical Site 527, West Lafayette

75034

Arcutis Clinical Site 519, Frisco

76001

Arcutis Clinical Site 506, Arlington

77030

Arcutis Clinical Site 505, Houston

85255

Arcutis Clinical Site 504, Scottsdale

90017

Arcutis Site 518, Los Angeles

90057

Arcutis Clinical Site 508, Los Angeles

92688

Arcutis Clinical Site 511, Rancho Santa Margarita

92708

Arcutis Clinical Site 509, Fountain Valley

MG5-1X8

Arcutis Clinical Site 521, Toronto

Unknown

Arcutis Clinical Site 530, Santo Domingo